We are live on ! Find out more

PLYX

Polaryx Therapeutics Inc

PLYX

Market cap $103M

2.07 USD

0.00

0%

At close Updated Sep 30, 4:00 PM EDT

Pre-market

After hours

2.07

0.00

0%

1 day

0%

5 days

-2.36%

1 month

2.99%

3 months

-22.18%

6 months

-68.68%

Year to date

-94.09%

1 year

-94.09%

5 years

-94.09%

10 years

-94.09%

About: Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer

Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles

Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer

Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial

Company on track to initiate SOTERIA trial in the second half of 2026 Clinical development activities advancing following FDA authorization, CRO engagement and Fast Track Designation across all four planned indication PARAMUS, NJ, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric lysosomal storage disorders (“LSDs”), today provided an operational readiness update for SOTERIA, its Phase 2 basket trial evaluating lead candidate PLX-200 across four rare pediatric LSDs. Polaryx continues to advance clinical trial start-up activities in collaboration with its contract research organization (CRO) and remains focused on initiating SOTERIA in the fourth quarter of 2026.

Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial

Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial

PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announced that it has closed a private investment in public equity (“PIPE”) financing resulting in proceeds of $10 million. The PIPE financing closed on May 28, 2026.

Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial

Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards

Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award Winner Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award Winner

Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards

Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference

PARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), today announced its participation in the National Tay-Sachs & Allied Diseases Association (NTSAD) Annual Family Conference, taking place April 30 through May 3, 2026, at the Hyatt Regency in Reston, Virginia. “The NTSAD Annual Family Conference is an important opportunity to connect directly with the families and advocates at the heart of the rare disease community,” said Alex Yang, J.D.

Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II).

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care

Company selected as a Diamond honoree for Excellence in Pediatric Care Company selected as a Diamond honoree for Excellence in Pediatric Care

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care

Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference

PARAMUS, NJ, April 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces that members of the executive team will be participating in the 25th Annual Needham Virtual Healthcare Conference.

Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference

Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)

PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric lysosomal storage disorders (“LSDs”), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PLX-200 for the treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease).

Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)

Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events

PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces its participation in two upcoming events supporting the Krabbe disease community. These events reflect Polaryx's ongoing commitment to advancing research and strengthening engagement with patients, caregivers, and clinicians.

Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events

See News Rankings

Price charts implemented using Lightweight Charts™